Celcuity INC 8-K filings

Celcuity Inc. has successfully priced an upsized offering of $575 million in aggregate principal amount of 0.250% Convertible Senior Notes due 2032, with net proceeds intended for debt repayment and general corporate purposes.

Celcuity Inc. announced detailed Phase 3 VIKTORIA-1 trial results for gedatolisib, showing a significant improvement in progression-free survival for advanced breast cancer patients.

Celcuity Inc. announces the appointment of Charles (Chip) R. Romp to its Board of Directors, increasing the board size to eight members.

Celcuity Inc. announced the approval of its 2026 Stock Incentive Plan and Amended and Restated 2017 Employee Stock Purchase Plan by stockholders at the 2026 Annual Meeting.

Celcuity announced that its Phase 3 VIKTORIA-1 trial met its primary endpoint, showing improved progression-free survival in PIK3CA mutant breast cancer patients.

Celcuity Inc. announced its fourth quarter and full year 2025 financial results, alongside a corporate update highlighting FDA Priority Review for gedatolisib and positive Phase 3 clinical trial data.

Celcuity Inc. has expanded its Board of Directors to eight members with the appointment of Charles R. Romp, an industry veteran with over 25 years of oncology commercialization experience.

Celcuity Inc. announced the submission of its New Drug Application to the U.S. FDA for gedatolisib in HR+/HER2PIK3CA wild-type advanced breast cancer.

Celcuity Inc. announced positive Phase 3 VIKTORIA-1 trial results for gedatolisib in breast cancer, regulatory progress, and a strengthened balance sheet, despite increased operating expenses in Q3 2025.

Celcuity Inc. announced detailed positive results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 clinical trial for gedatolisib in advanced breast cancer, initiating a rolling NDA submission.

Celcuity Inc. announced an amendment to its senior secured credit facility, increasing total capital availability to $500 million and extending the maturity date to November 2029.

Celcuity Inc. announced positive Phase 3 clinical trial data for gedatolisib in breast cancer, secured significant financing, and reported increased operating expenses for Q2 2025.

Celcuity Inc. has successfully completed a public offering of $201.25 million aggregate principal amount of 2.750% Convertible Senior Notes due 2031, including the full exercise of the underwriters' over-allotment option.

Celcuity Inc. announced the successful pricing and expected closing of concurrent public offerings, raising approximately $248.7 million in net proceeds from common stock, pre-funded warrants, and convertible senior notes to fund its clinical-stage oncology programs.

Celcuity Inc. announced a proposed concurrent public offering to raise $225 million through convertible senior notes and common stock, alongside an amendment to its loan agreement to facilitate the offering and allow for an additional $30 million debt draw.

Celcuity Inc. announced positive topline results from its Phase 3 VIKTORIA-1 clinical trial, demonstrating statistically significant and clinically meaningful improvements in progression-free survival for gedatolisib in HR+/HER2PIK3CA wild-type advanced breast cancer.

Celcuity Inc. announced preliminary positive clinical data from two early phase studies of gedatolisib for metastatic castration-resistant prostate cancer and HER2+ metastatic breast cancer, showing promising efficacy and tolerability.

Celcuity Inc. stockholders approve an amendment to the 2017 Stock Incentive Plan, increasing the share pool by 3,000,000 to attract and retain talent.

Celcuity Inc. announced its first quarter 2025 financial results, highlighting progress in clinical trials and a collaboration with Dana Farber Cancer Institute and Massachusetts General Hospital.

Celcuity Inc. announces its Q4 and full year 2024 financial results, highlighting progress in its clinical trials and a strong cash position to fund operations through 2026.

Celcuity Inc. has filed a prospectus supplement to offer up to $125 million in common stock, following the effectiveness of a new shelf registration statement.

Celcuity Inc. announced its third quarter 2024 financial results, highlighted by the full enrollment of the PIK3CA wild-type cohort in the VIKTORIA-1 trial and a strong cash position.

Celcuity Inc. has increased its authorized common stock from 65 million to 95 million shares after receiving stockholder approval at a special meeting on October 7, 2024.

Celcuity reported its second quarter 2024 financial results, highlighted by a $129 million capital raise and progress in its clinical trials, including the initiation of a Phase 3 trial for gedatolisib.

Celcuity Inc. successfully closed a public offering of 3,871,000 shares of common stock, raising approximately $56.2 million in net proceeds to support working capital, research and development, and clinical trial expenditures.

Celcuity Inc. has secured up to $180 million in debt financing to support the initiation of a Phase 3 clinical trial for its drug gedatolisib in treating advanced breast cancer.

Celcuity Inc. announced its first quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position.

Celcuity Inc. stockholders approved an increase in shares allocated for issuance under the 2017 Stock Incentive Plan and an increase in the number of incentive award shares at the 2024 Annual Meeting.

Celcuity Inc. has amended its loan agreement to extend the deadline for drawing down a $10 million term loan to June 1, 2024.

Celcuity Inc. announced its fourth quarter and full year 2023 financial results, highlighting increased spending on clinical trials and securing funding to support operations into the first half of 2026.